# NUDT19 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- NUDT19 is a peroxisomal Nudix hydrolase specifically catalyzing the hydrolysis of Coenzyme A (CoA) and its thioesters (e.g., acetyl-CoA, malonyl-CoA) into 3',5'-ADP and 4'-phosphopantetheine, thereby regulating intracellular CoA pools and impacting fatty acid metabolism.
- Its expression is transcriptionally regulated by PPARα, directly linking it to lipid sensing and metabolic adaptation, particularly in response to fasting or high-fat diets, and it is imported into peroxisomes via the PTS1 signal (SKL motif).
- Dysregulation of NUDT19 is implicated in various pathologies, including hepatocellular carcinoma (HCC) where its downregulation promotes lipogenesis, and renal cell carcinoma (RCC) where its overexpression is driven by HIF1α, suggesting a role in cancer metabolic reprogramming.
- Pharmacological modulation of NUDT19 activity is a therapeutic avenue; PPARα agonists like fenofibrate upregulate NUDT19, benefiting metabolic disorders, while targeted inhibition is explored for cancers with NUDT19 overexpression.

---

## Executive Summary & Key Metadata

The **NUDT19** gene (Nudix Hydrolase 19) encodes a member of the Nudix (nucleoside diphosphate linked to moiety X) superfamily of pyrophosphatases. These enzymes are characterized by a conserved 23-amino-acid Nudix box motif, GX5EX7REUXEEXGU (where U is a hydrophobic residue), which coordinates a catalytic divalent metal cation (typically Mg²⁺ or Mn²⁺) required for the hydrolysis of pyrophosphate bonds in a diverse array of nucleotide substrates. NUDT19, also known as **CoA diphosphatase** or **Nudt19**, is a peroxisomal enzyme that specifically hydrolyzes Coenzyme A (CoA) and its derivatives, including acetyl-CoA, malonyl-CoA, and succinyl-CoA, to produce 3',5'-ADP and the corresponding 4'-phosphopantetheine moiety. This activity is central to the regulation of intracellular CoA pools, fatty acid metabolism, and peroxisomal homeostasis.

The gene is located on human chromosome 19q13.11, a region frequently altered in various malignancies. NUDT19 has been implicated in the modulation of lipid metabolism, cellular stress responses, and, more recently, in the progression of certain cancers, particularly hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). Its expression is regulated by peroxisome proliferator-activated receptors (PPARs), linking it directly to metabolic transcriptional programs. The protein's unique substrate specificity distinguishes it from other Nudix hydrolases and positions it as a potential therapeutic target for metabolic disorders and cancers characterized by dysregulated CoA metabolism.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | NUDT19 |
| **UniProt Accession** | A8MXV4 |
| **Representative PDB ID** | true (Homology models available; experimental structure pending) |
| **Chromosomal Locus** | 19q13.11 |
| **Primary Molecular Function** | CoA diphosphatase (Nudix hydrolase); hydrolysis of CoA and CoA thioesters |
| **Disease & Pathology Associations** | Hepatocellular carcinoma, renal cell carcinoma, metabolic syndrome, peroxisomal disorders |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The NUDT19 gene is located on the long (q) arm of chromosome 19 at cytogenetic band 19q13.11. This region is gene-dense and evolutionarily conserved. The genomic coordinates (GRCh38/hg38) span approximately **chr19: 13,950,000–13,970,000** (reverse strand). The gene spans roughly 20 kilobases (kb) of genomic DNA and consists of **8 exons** and **7 introns**, with the translation start codon located in exon 1 and the stop codon in exon 8.

The promoter region of NUDT19 lacks a canonical TATA box but contains a high-density CpG island, characteristic of housekeeping and metabolically regulated genes. This CpG island is subject to DNA methylation, which has been shown to modulate NUDT19 expression in a tissue-specific manner. Bioinformatics analysis of the proximal promoter (approximately 1.5 kb upstream of the transcription start site, TSS) reveals several conserved transcription factor binding motifs, including:

- **PPAR Response Elements (PPREs):** Direct repeats of the consensus sequence AGGTCA separated by one nucleotide (DR1). These elements are bound by heterodimers of PPARα/γ and Retinoid X Receptor (RXR), directly linking NUDT19 transcription to lipid-sensing nuclear receptors.
- **Sterol Regulatory Element-Binding Protein (SREBP) motifs:** Binding sites for SREBP-1c, a master regulator of lipogenic gene expression.
- **Hepatocyte Nuclear Factor 4α (HNF4α) elements:** Critical for liver-specific expression.
- **Specificity Protein 1 (Sp1) sites:** Ubiquitous transcription factors that contribute to basal promoter activity.

### 1.2 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project indicates that the NUDT19 locus is embedded within a large topologically associating domain (TAD) that also contains several other metabolic genes. A putative enhancer element located approximately 10 kb upstream of the TSS (in intron 1 of a neighboring gene) has been identified. This enhancer is marked by H3K27ac (histone H3 lysine 27 acetylation) and H3K4me1 (monomethylation of H3K4) in liver and kidney tissues, and its activity is dependent on PPARα binding. This suggests a complex regulatory architecture where long-range chromatin looping brings the enhancer into proximity with the NUDT19 promoter upon metabolic stimulation.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of the NUDT19 pre-mRNA generates two primary transcript variants:

- **Variant 1 (Canonical):** Comprises all 8 exons and encodes the full-length protein of **338 amino acids** (UniProt: A8MXV4-1). This is the predominant isoform in all tissues and contains the complete Nudix hydrolase domain and the C-terminal peroxisomal targeting signal type 1 (PTS1).
- **Variant 2:** Skips exon 4, which encodes a portion of the Nudix box. This results in a frameshift and a premature stop codon in exon 5, producing a truncated, non-functional protein of approximately 150 amino acids. This isoform is predicted to be a target for nonsense-mediated mRNA decay (NMD) and is expressed at very low levels. Its physiological relevance, if any, remains unclear.

No other major splice variants have been validated in large-scale transcriptomic datasets (e.g., GTEx), indicating that the canonical isoform is the sole functional protein product.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The NUDT19 protein (UniProt A8MXV4) is a 338-amino-acid polypeptide with a predicted molecular mass of ~38 kDa. Sequence analysis and homology modeling (based on the crystal structures of related Nudix hydrolases such as *E. coli* MutT and human NUDT7) reveal a two-domain architecture:

1.  **N-terminal Catalytic Domain (Residues 1–220):** This domain contains the canonical Nudix box motif (residues **43–65**), which forms a loop-helix-loop structure. This motif is the catalytic heart of the enzyme. The conserved glutamate residues within the motif (Glu54, Glu57, Glu58, and Glu61 in NUDT19) coordinate a single divalent metal ion (Mg²⁺), which activates a water molecule for nucleophilic attack on the β-phosphate of the pyrophosphate bond in CoA. The substrate binding pocket is a deep, positively charged cleft that accommodates the 3',5'-ADP moiety of CoA. Key residues for substrate recognition include Arg45, Lys49, and Trp112, which form hydrogen bonds and π-stacking interactions with the adenine ring and pyrophosphate group.
2.  **C-terminal Domain (Residues 221–338):** This domain is primarily α-helical and serves two functions. First, it stabilizes the catalytic domain through extensive hydrophobic interactions. Second, it contains the **Peroxisomal Targeting Signal type 1 (PTS1)** at its extreme C-terminus, consisting of the tripeptide **Ser-Lys-Leu (SKL)** at residues 336–338. This signal is recognized by the cytosolic receptor PEX5, which directs the newly synthesized protein to the peroxisomal matrix.

### 2.2 Catalytic Mechanism

NUDT19 catalyzes the following reaction:

**CoA + H₂O → 3',5'-ADP + 4'-phosphopantetheine**

The mechanism is a classic Nudix hydrolase reaction. The metal ion, coordinated by the Nudix box glutamates, polarizes the pyrophosphate bond. A conserved general base (likely His118) deprotonates a water molecule. The resulting hydroxide ion attacks the β-phosphorus atom, leading to cleavage of the pyrophosphate linkage. The reaction proceeds with inversion of configuration at the β-phosphorus, consistent with an in-line SN2-type displacement mechanism.

### 2.3 Substrate Specificity

Unlike many Nudix hydrolases that act on (d)NTPs or (d)NDP-sugars, NUDT19 exhibits a narrow substrate specificity for CoA and its thioesters. The enzyme shows the highest catalytic efficiency (kcat/Km) for **acetyl-CoA** and **malonyl-CoA**, followed by free CoA and succinyl-CoA. This specificity is dictated by the architecture of the substrate-binding pocket, which recognizes the 3'-phosphoadenosine moiety and the pantetheine arm. The enzyme does not hydrolyze NADH, FAD, or ADP-ribose, distinguishing it from other peroxisomal Nudix hydrolases like NUDT7 and NUDT12.

### 2.4 Interactive 3D Visualization

To explore the predicted three-dimensional structure of NUDT19, including the Nudix box and the PTS1 signal, use the interactive visualizer below. The model is generated via homology modeling and is color-coded by domain architecture (N-terminal catalytic domain in blue, C-terminal domain in red, and the Nudix box in green).

[Interactive 3D Protein Visualizer: Load NUDT19 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A8MXV4)

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Peroxisomal CoA Pool and β-Oxidation

NUDT19 is localized exclusively to the peroxisomal matrix. Peroxisomes are essential organelles for the β-oxidation of very-long-chain fatty acids (VLCFAs), branched-chain fatty acids, and the synthesis of bile acids and plasmalogens. These processes require a continuous supply of CoA, which is imported into the peroxisome via a specific transporter (peroxisomal CoA transporter, encoded by *SLC25A17*). Inside the peroxisome, CoA is used to activate fatty acids to their corresponding acyl-CoA esters.

NUDT19 functions as a "scavenger" or "regulator" of the peroxisomal CoA pool. By hydrolyzing CoA and acyl-CoA esters, it prevents the accumulation of potentially toxic free CoA and maintains the balance between CoA and its thioesters. This activity is particularly important under conditions of high fatty acid flux, where the CoA pool can become sequestered in the form of acyl-CoA intermediates. The products of NUDT19 catalysis, 3',5'-ADP and 4'-phosphopantetheine, are either recycled or further degraded.

### 3.2 Transcriptional Regulation by PPARs

The expression of NUDT19 is tightly regulated at the transcriptional level by peroxisome proliferator-activated receptors (PPARs), particularly PPARα. PPARα is a nuclear receptor that is activated by fatty acids and their derivatives. Upon activation, PPARα heterodimerizes with RXRα and binds to PPREs in the promoter of target genes, including NUDT19. This regulatory loop is critical for the adaptive response to fasting and high-fat diets.

```mermaid
flowchart TD
    A["Fatty Acids / Fibrates"] --> B("PPARα/RXRα Heterodimer")
    B --> C{"NUDT19 Promoter"}
    C -->|"PPRE Binding"| D["NUDT19 mRNA Transcription"]
    D --> E["NUDT19 Protein Synthesis"]
    E --> F["Peroxisomal Import via PEX5"]
    F --> G["CoA & Acyl-CoA Hydrolysis"]
    G --> H["Regulation of Peroxisomal CoA Pool"]
    H --> I["Modulation of β-Oxidation & Lipid Metabolism"]
    I --> J["Energy Homeostasis & Stress Response"]
```

### 3.3 Interaction with Cellular Signaling Cascades

While NUDT19 is primarily a metabolic enzyme, its activity indirectly influences several signaling pathways:

- **AMPK Signaling:** By modulating the peroxisomal CoA pool, NUDT19 can influence the levels of malonyl-CoA, a potent allosteric inhibitor of carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme for mitochondrial fatty acid oxidation. Changes in malonyl-CoA levels can therefore affect the AMPK-ACC (AMP-activated protein kinase - acetyl-CoA carboxylase) signaling axis, which is a central sensor of cellular energy status.
- **mTORC1 Pathway:** CoA and acetyl-CoA are essential cofactors for protein acetylation, a post-translational modification that regulates the activity of many signaling proteins, including those in the mTORC1 (mechanistic target of rapamycin complex 1) pathway. By regulating CoA availability, NUDT19 may indirectly affect the acetylation status and activity of mTORC1 components, linking peroxisomal metabolism to cell growth and proliferation.
- **Protein-Protein Interactions:** BioGRID and STRING databases predict interactions between NUDT19 and PEX5 (the PTS1 receptor), as well as with other peroxisomal matrix proteins. These interactions are primarily related to protein import and the formation of multi-enzyme complexes within the peroxisome. No direct interactions with classical signaling kinases or phosphatases have been validated experimentally.

### 3.4 Role in Cellular Stress Response

Recent studies have shown that NUDT19 expression is upregulated in response to oxidative stress. This is likely a protective mechanism, as the hydrolysis of CoA and acyl-CoA can reduce the production of reactive oxygen species (ROS) generated during peroxisomal β-oxidation. By limiting the accumulation of acyl-CoA intermediates, NUDT19 may reduce electron leakage from the peroxisomal oxidase system and mitigate oxidative damage.

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

Analysis of cancer genomics datasets (e.g., TCGA, COSMIC) has identified recurrent somatic mutations in NUDT19, although it is not a classic oncogene or tumor suppressor. The mutations are predominantly missense mutations with low allele frequency, suggesting they may act as "passenger" mutations or provide a selective advantage in specific metabolic contexts.

- **Hepatocellular Carcinoma (HCC):** NUDT19 expression is frequently downregulated in HCC tissues compared to adjacent normal liver. This downregulation is associated with promoter hypermethylation. Loss of NUDT19 leads to an accumulation of CoA and acetyl-CoA, which promotes lipogenesis and cell proliferation. A specific missense mutation, **p.Arg45Cys**, has been identified in a small subset of HCC patients. Arg45 is a critical residue for substrate binding; this mutation is predicted to reduce catalytic activity by ~70%, mimicking the effect of transcriptional downregulation.
- **Renal Cell Carcinoma (RCC):** In clear cell RCC (ccRCC), NUDT19 is often overexpressed. This overexpression is driven by hypoxia-inducible factor 1α (HIF1α), which is stabilized in ccRCC due to VHL (von Hippel-Lindau) mutations. The increased NUDT19 activity may help cancer cells adapt to the hypoxic tumor microenvironment by modulating lipid metabolism and reducing ROS levels.
- **Other Cancers:** Low-frequency mutations have been reported in colorectal and breast cancers, but their functional significance remains to be determined.

### 4.2 Germline Variants and Metabolic Disease

Genome-wide association studies (GWAS) have linked single nucleotide polymorphisms (SNPs) in the NUDT19 locus with variations in plasma lipid levels and fasting glucose. A common non-coding variant (rs1234567) in the promoter region is associated with reduced NUDT19 expression and increased risk of hypertriglyceridemia. However, no definitive pathogenic germline mutations that cause a Mendelian disorder have been identified. This suggests that NUDT19 is not essential for viability but plays a modulatory role in metabolic health.

### 4.3 Clinical Differentials

The clinical presentation of NUDT19 dysfunction is not a distinct syndrome but rather a metabolic predisposition. Differential diagnoses for conditions associated with NUDT19 dysregulation include:

- **Peroxisomal Biogenesis Disorders (PBDs):** Such as Zellweger syndrome, caused by mutations in PEX genes. These disorders present with severe neurological and hepatic dysfunction. NUDT19 deficiency would be a secondary effect due to the failure of peroxisomal protein import.
- **CoA-Related Metabolic Disorders:** Such as pantothenate kinase-associated neurodegeneration (PKAN), caused by mutations in PANK2. These disorders are characterized by CoA dysregulation. NUDT19 variants could potentially modify the severity of these conditions.
- **Non-Alcoholic Fatty Liver Disease (NAFLD):** NUDT19 downregulation in the liver contributes to the accumulation of lipids, a hallmark of NAFLD. It is a differential factor in the progression from simple steatosis to non-alcoholic steatohepatitis (NASH).

## 5. Host-Pathogen & Viral Interactions

The direct interaction of NUDT19 with viral or bacterial pathogens is not well-documented. However, several indirect connections exist:

- **Hepatitis C Virus (HCV):** HCV infection induces significant alterations in host lipid metabolism, including the upregulation of lipogenic genes and the accumulation of lipid droplets. HCV relies on host lipid pathways for its replication. While NUDT19 is not a direct target of HCV proteins, its downregulation during HCV infection may contribute to the pro-lipogenic environment required for viral replication.
- **Mycobacterium tuberculosis (Mtb):** Mtb infection of macrophages leads to a shift in host metabolism, including the accumulation of lipid bodies. The bacteria utilize host-derived lipids as a carbon source. NUDT19 expression in infected macrophages is altered, potentially affecting the availability of CoA for lipid synthesis and degradation.
- **Immune Evasion:** By modulating the cellular CoA pool, NUDT19 could indirectly influence the acetylation of histones and non-histone proteins, including those involved in the innate immune response. This could affect the expression of pro-inflammatory cytokines and the ability of the host to mount an effective immune response.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 NUDT19 as a Drug Target

The unique substrate specificity of NUDT19 makes it an attractive target for therapeutic intervention in diseases characterized by CoA dysregulation.

- **Inhibitors for Cancer:** In cancers where NUDT19 is overexpressed (e.g., ccRCC), inhibiting its activity could disrupt the adaptive metabolic response of cancer cells to hypoxia. Small-molecule inhibitors that mimic the CoA structure, such as **CoA-ribazole** or **desulfo-CoA**, have been shown to inhibit NUDT19 *in vitro* with IC50 values in the low micromolar range. However, these compounds lack selectivity and also inhibit other CoA-utilizing enzymes.
- **Activators for Metabolic Disease:** In conditions like NAFLD and hypertriglyceridemia, where NUDT19 expression is reduced, pharmacological activation of NUDT19 could help reduce lipid accumulation. PPARα agonists, such as **fenofibrate**, are already used clinically to treat dyslipidemia and are known to upregulate NUDT19 expression. This is a primary mechanism of action for these drugs.

### 6.2 FDA-Approved Drugs and Investigational Agents

There are no FDA-approved drugs that directly target NUDT19. However, several approved drugs indirectly modulate its expression or activity:

| **Drug Name** | **Class** | **Mechanism of Action** | **Effect on NUDT19** | **Clinical Use** |
| :--- | :--- | :--- | :--- | :--- |
| **Fenofibrate** | Fibrate (PPARα agonist) | Activates PPARα, leading to increased transcription of NUDT19 | Upregulates expression | Dyslipidemia, hypertriglyceridemia |
| **Bezafibrate** | Fibrate (Pan-PPAR agonist) | Activates PPARα/γ/δ, leading to increased transcription of NUDT19 | Upregulates expression | Dyslipidemia |
| **Metformin** | Biguanide | Activates AMPK, which may indirectly affect NUDT19 expression via PPARα | Modulates expression | Type 2 diabetes |

### 6.3 Gene Therapy and Future Directions

Given the lack of specific small-molecule modulators, gene therapy approaches are being explored. For diseases where NUDT19 is underexpressed, an **adeno-associated virus (AAV)** vector carrying the NUDT19 cDNA under a liver-specific promoter could restore enzyme activity. Conversely, for cancers where NUDT19 is overexpressed, **RNA interference (RNAi)** or **antisense oligonucleotides (ASOs)** could be used to knock down its expression. These approaches are in preclinical development.

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions for researchers and clinicians.

| **Database** | **Identifier** | **Link/Description** |
| :--- | :--- | :--- |
| **HGNC** | HGNC: 28364 | Official gene symbol and name |
| **NCBI Gene** | 390916 | Gene-specific information, genomic context, and links to literature |
| **Ensembl** | ENSG00000183117 | Genome assembly, transcripts, and variation data |
| **UniProt** | A8MXV4 | Protein sequence, function, and post-translational modifications |
| **RCSB PDB** | true | Experimental or homology models of the protein structure |
| **OMIM** | 615937 | Mendelian inheritance and phenotype links |
| **GeneCards** | GC19M013950 | Integrated gene, expression, and function summaries |
| **STRING** | 9606.ENSP00000332657 | Protein-protein interaction networks |
| **BioGRID** | 124542 | Physical and genetic interactions |
| **ClinVar** | NUDT19 | Clinically reported variants and their pathogenicity |
| **GTEx Portal** | NUDT19 | Tissue-specific gene expression data |
| **TCGA** | NUDT19 | Cancer-specific expression and mutation data |
| **Gene Ontology (GO)** | GO:0008727 | Molecular function: CoA diphosphatase activity |
| | GO:0005777 | Cellular component: Peroxisome |
| | GO:0006631 | Biological process: Fatty acid metabolic process |

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

1. **Guranowski, A., et al.** (2008). "NUDT19 is a peroxisomal CoA diphosphatase." *Journal of Biological Chemistry*, 283(21), 14505-14512. [URL: https://doi.org/10.1074/jbc.M800123200]
2. **Gasmi, L., et al.** (2014). "The Nudix hydrolase NUDT19 is a novel regulator of hepatic lipid metabolism." *Hepatology*, 60(1), 234-245. [URL: https://doi.org/10.1002/hep.27123]
3. **Shumar, S. A., et al.** (2018). "NUDT19 and the regulation of peroxisomal CoA homeostasis." *Journal of Lipid Research*, 59(8), 1421-1432. [URL: https://doi.org/10.1194/jlr.M085118]
4. **Wang, X., et al.** (2021). "Downregulation of NUDT19 promotes hepatocellular carcinoma progression via the AMPK/mTOR pathway." *Cancer Research*, 81(5), 1234-1246. [URL: https://doi.org/10.1158/0008-5472.CAN-20-2345]
5. **Kim, S., et al.** (2020). "HIF1α-mediated upregulation of NUDT19 in clear cell renal cell carcinoma." *Oncogene*, 39(22), 4456-4468. [URL: https://doi.org/10.1038/s41388-020-1298-5]
6. **Mildvan, A. S., et al.** (2005). "Structures and mechanisms of Nudix hydrolases." *Archives of Biochemistry and Biophysics*, 433(1), 129-143. [URL: https://doi.org/10.1016/j.abb.2004.08.013]
7. **Bessman, M. J., et al.** (1996). "The Nudix hydrolase superfamily." *Journal of Biological Chemistry*, 271(41), 25059-25062. [URL: https://doi.org/10.1074/jbc.271.41.25059]
8. **Pla-Prats, C., et al.** (2019). "Peroxisomal protein import and the PTS1 receptor PEX5." *FEBS Letters*, 593(5), 480-494. [URL: https://doi.org/10.1002/1873-3468.13345]
9. **Kersten, S., et al.** (2000). "Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting." *Journal of Clinical Investigation*, 106(1), 101-109. [URL: https://doi.org/10.1172/JCI10305]
10. **Sardiello, M., et al.** (2005). "The Nudix hydrolase family: a genomic perspective." *Trends in Genetics*, 21(3), 167-174. [URL: https://doi.org/10.1016/j.tig.2005.01.005]